An overview of infectious complications in children on new biologic response-modifying agents. Issue 5 (October 2010)

• Record Type: Journal Article
• Authors: Abinun, Mario
• Is Part Of: Pediatric health. Volume 4:Issue 5(2010)
• Page Start: 509
• Page End: 517
• Publication Date: 2010-10
• Subjects: biologic response-modifying agents -- biologics -- children -- cytokines -- immune dysregulation -- infection -- inflammation -- interleukins -- rheumatic disorders -- TNF-α; Pediatrics -- Periodicals; 618.920005
• DOI: 10.2217/phe.10.57
• Languages: English
• ISSNs: 1745-5111

Abstract

The clinical need for better treatments as well as the significant progress in understanding the pathophysiology of inflammation on one hand, and the progressive development of biotechnology on the other, were the driving force for the emergence of new treatments for autoimmune disorders at the beginning of the 21st century, heralding the 'age of biologic response modifying agents' or biologics. This new class of drugs, although in use for just over a decade, has revolutionized the treatment of many inflammatory disorders, such as rheumatic, connective tissue disorders, autoimmune and autoinflammatory diseases. They have already made an immense impact on the quality of life of patients experiencing many years of combined immunosuppressive and anti-inflammatory treatments for chronic and often debilitating diseases. As these drugs were developed with the aim of altering specific components in the immune system function and, in particular, the inflammatory response, it is not surprising that infectious complications, including the severe and unusual, are among the serious side effects alongside other features of dysregulated immune system function, such as autoimmunity, lymphoproliferation and malignancy. The aim of this article is to highlight and anticipate further the infectious risks of the most commonly used biologics in children.